Drugs for Gastroschisis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 31)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Glycerol |
Approved, Investigational |
Phase 4 |
|
56-81-5 |
753
|
Synonyms:
1,2,3-propanetriol
1,2,3-trihydroxypropane
1,2,3-Trihydroxypropane
Bulbold
Cristal
E 422
Emery 916
Glyceol Opthalgan
Glycerin
Glycerin, anhydrous
Glycerin,anhydrous
Glycerine
glycérine
Glycerinum
Glyceritol
Glycerol
|
glycérol
Glycyl alcohol
Glyrol
Glysanin
Glyzerin
IFP
Incorporation factor
Mackstat H 66
Monoctanoin component D
Ölsüß
Osmoglyn
Pricerine 9091
Propanetriol
RG-S
Trihydroxypropane
Tryhydroxypropane
|
|
2 |
|
Protective Agents |
|
Phase 4 |
|
|
|
3 |
|
Dopamine |
Approved |
Phase 3 |
|
51-61-6, 62-31-7 |
681
|
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
hydroxytyramine
|
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
4 |
|
Metoclopramide |
Approved, Investigational |
Phase 3 |
|
364-62-5 |
4168
|
Synonyms:
(metaclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide
(metoclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide
1,5-Dimethyl-2-phenyl-1,2-dihydro-pyrazol-3-one
2576-84-3 (di-hydrochloride)
2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide
2-Methoxy-4-amino-5-chloro-N,N-dimethylaminoethyl)benzamide
2-methoxy-5-chloroprocainamide
2-Methoxy-5-chloroprocainamide
364-62-5
4 Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide
4-Amino-5-chloro-2-methoxy-N-(beta-diethylaminoethyl)benzamide
4-amino-5-chloro-2-methoxy-N-(β-diethylaminoethyl)benzamide
4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide
4-amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide
4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide
4-amino-5-chloro-N-(2-diethylaminoethyl)-2-methoxybenzamide
4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide
4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (Mcp)
4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (metoclopramide)
4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide(Metoclopramide)
4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
54143-57-6 (mono-hydrochloride, mono-hydrate)
5-Chloro-2-methoxyprocainamide
7232-21-5 (mono-hydrochloride)
AB00053498
AC1L1HKD
AKOS000280832
Apo-Metoclop
ARONIS24307
Benzamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxy- (9CI)
Biomol-NT_000082
bmse000779
BPBio1_000217
BPBio1_001100
BRD-K75641298-001-01-5
BRD-K75641298-003-05-2
BRN 1884366
BSPBio_000197
BSPBio_002027
C07868
C14H22ClN3O2
CAS-7232-21-5
Cerucal
CHEBI:107736
CHEMBL86
CID4168
Clopra
CLOPRA-"YELLOW"
Clopra-Yellow
Clopromate
D00726
DB01233
DEL
DEL 1267
DivK1c_000069
Duraclamid
EINECS 206-662-9
Elieten
Elieten (TN)
Emetid
Emitasol
Emperal
Eucil
Gastrese
Gastrobid
Gastromax
Gastronerton
Gastrosil
Gastrotablinen
Gastrotem
Gastro-Timelets
HMS2089G16
IDI1_000069
Imperan
KBio1_000069
KBio2_002118
KBio2_004686
|
KBio2_007254
KBio3_001527
KBioGR_001307
KBioSS_002118
L001078
Lopac0_000762
Lopac-M-0763
LS-20038
Maxeran
Maxolon
Meclopran
Metaclopramide
Metaclopromide
Metamide
Methochlopramide
Methoclopramide
Metochlopramide
Metoclol
Metoclopramida
Metoclopramida [INN-Spanish]
metoclopramide
Metoclopramide (JP15/INN)
Metoclopramide [INN:BAN:JAN]
Metoclopramide Hcl
Metoclopramide Hydrochloride
Metoclopramide Intensol
Metoclopramide Monohydrochloride, Monohydrate
Metoclopramide Omega
Metoclopramidum
Metoclopramidum [INN-Latin]
Metocobil
Metramid
MolPort-000-883-854
Moriperan
Mygdalon
N-(Diethylaminoethyl)-2-methoxy-4-amino-5-chlorobenzamide
NCGC00015643-01
NCGC00015643-02
NCGC00015643-03
NCGC00015643-08
NCGC00024440-03
NCGC00024440-04
NCI60_003185
Neu-Sensamide
NINDS_000069
Nu-Metoclopramide
o-Anisamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)- (8CI)
Octamide
Parmid
Paspertin
Peraprin
Plasil
Plasil (pharmaceutical)
Pms-Metoclopramide
Pramidin
Pramiel
Pramin
Prestwick0_000209
Prestwick1_000209
Prestwick2_000209
Prestwick3_000209
Primperan
Reclomide
Reglan
Reliveran
SPBio_001740
SPBio_002118
Spectrum_001638
Spectrum2_001720
Spectrum3_000504
Spectrum4_000964
Spectrum5_001449
ST024773
Terperan
Terperan (TN)
UNII-L4YEB44I46
|
|
5 |
|
Antiemetics |
|
Phase 3 |
|
|
|
6 |
|
Autonomic Agents |
|
Phase 3 |
|
|
|
7 |
|
Dopamine Agents |
|
Phase 3 |
|
|
|
8 |
|
Dopamine Antagonists |
|
Phase 3 |
|
|
|
9 |
|
Dopamine D2 Receptor Antagonists |
|
Phase 3 |
|
|
|
10 |
|
Gastrointestinal Agents |
|
Phase 3,Phase 1,Phase 2 |
|
|
|
11 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
12 |
|
Peripheral Nervous System Agents |
|
Phase 3 |
|
|
|
13 |
|
Bilirubin |
|
Phase 2, Phase 3 |
|
635-65-4 |
5280352
|
Synonyms:
(4Z,15Z)-Bilirubin IXa
(Z,Z)-Bilirubin IXa
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-Biline-8,12-dipropionate
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-Biline-8,12-dipropionic acid
2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-Biline-8,12-dipropanoate
2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-Biline-8,12-dipropanoic acid
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoate
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-[(Z)-(3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl]-1H-pyrrol-2-yl)methyl)-4-methyl-5-[(Z)-(4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene
|
3-[2-[[3-(2-Carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate
3-[2-[[3-(2-Carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
3-[2-[[3-(2-Carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate
3-[2-[[3-(2-Carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
Bilirubin
Bilirubin IX-alpha
Cholerythrin
Hematoidin
|
|
14 |
|
Fat Emulsions, Intravenous |
|
Phase 2, Phase 3 |
|
|
|
15 |
|
Liver Extracts |
|
Phase 2, Phase 3 |
|
|
|
16 |
|
Omega 3 Fatty Acid |
Nutraceutical |
Phase 2, Phase 3 |
|
|
|
17 |
|
glucagon |
|
Phase 1, Phase 2 |
|
|
|
18 |
|
Glucagon-Like Peptide 1 |
|
Phase 1, Phase 2 |
|
|
|
19 |
|
Hormone Antagonists |
|
Phase 1, Phase 2 |
|
|
|
20 |
|
Hormones |
|
Phase 1, Phase 2 |
|
|
|
21 |
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
Phase 1, Phase 2 |
|
|
|
22 |
|
Incretins |
|
Phase 1, Phase 2 |
|
|
|
23 |
|
Anti-Bacterial Agents |
|
|
|
|
|
24 |
|
Antibiotics, Antitubercular |
|
|
|
|
|
25 |
|
Micronutrients |
|
|
|
|
|
26 |
|
Pharmaceutical Solutions |
|
|
|
|
|
27 |
|
Trace Elements |
|
|
|
|
|
28 |
|
Vitamins |
|
|
|
|
|
29 |
|
Dialysis Solutions |
|
Early Phase 1 |
|
|
|
30 |
|
Bifidobacterium |
Nutraceutical |
|
|
|
|
31 |
|
lysine |
Nutraceutical |
|
|
|
|
Interventional clinical trials:
(show all 29)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Evaluation of Glycerin Suppositories to Improve Bowel Function in Gastroschisis |
Recruiting |
NCT03355326
|
Phase 4 |
Glycerin Suppository |
2 |
Prophylaxis of Ileostomy Closure Site Hernia by Placing Mesh |
Recruiting |
NCT02226887
|
Phase 4 |
|
3 |
The Use of Gastrografin to Help Alleviate Bowel Obstruction in Gastroschisis Patients. |
Not yet recruiting |
NCT03334578
|
Phase 4 |
Gastrografin |
4 |
Trial of AMNIOECHANGE in Gastroschisis Affected Foetuses |
Unknown status |
NCT00127946
|
Phase 3 |
|
5 |
Metoclopramide Pilot Trial |
Recruiting |
NCT02098915
|
Phase 3 |
intravenous metoclopramide |
6 |
Compassionate Use of Omegaven in Children |
Recruiting |
NCT02370251
|
Phase 2, Phase 3 |
Omegaven |
7 |
Evaluating the Use of a Silastic Spring-Loaded Silo for Infants With Gastroschisis |
Completed |
NCT00539292
|
Phase 2 |
|
8 |
Safety and Dosing Study of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure |
Terminated |
NCT01573286
|
Phase 1, Phase 2 |
Glucagon-Like Peptide 2;Glucagon like peptide-2 |
9 |
Music Therapy: An Adjunct To Gastroschisis Infants' Care |
Unknown status |
NCT01469208
|
|
|
10 |
Probiotics in Infants With Gastroschisis |
Unknown status |
NCT01316510
|
|
|
11 |
Elemental Formula in Neonates Post Small Bowel Resection: Improved Weaning From Total Parenteral Nutrition? |
Unknown status |
NCT01891279
|
|
|
12 |
Clinical and Biological Outcomes of Human Milk and Formula Intake After Gastroschisis Repair |
Completed |
NCT02575846
|
|
|
13 |
Children's Surgery in Sub-Saharan Africa |
Completed |
NCT03185637
|
|
|
14 |
ProLOVE - Prospective Randomized Study of Midline Incisional Hernia Treatment |
Completed |
NCT00472537
|
|
|
15 |
PREMAPIV : Intravesical Pressure Variation at Different Bladder Instillation Volumes in Newborn Children |
Completed |
NCT01296724
|
|
|
16 |
Determination of Lysine Requirement in the Parenterally Fed Neonate |
Completed |
NCT00779753
|
|
|
17 |
Silo Versus Primary Closure for Gastroschisis |
Recruiting |
NCT01506531
|
|
|
18 |
Oral Care in Infants With Gastroschisis |
Recruiting |
NCT03393832
|
|
|
19 |
Direct Peritoneal Resuscitation in Gastroschisis |
Recruiting |
NCT03205553
|
Early Phase 1 |
Investigational Treatment Group |
20 |
Gastroschisis Outcomes of Delivery (GOOD) Study |
Recruiting |
NCT02774746
|
|
|
21 |
Genetic Analysis of Congenital Diaphragmatic Disorders |
Recruiting |
NCT01243229
|
|
|
22 |
Sham Feeding Post-operative Infants |
Recruiting |
NCT03350022
|
|
|
23 |
Interest of the Manual Exploration as a Supplement to the Coelioscopy in the Evaluation of the Resectability of Peritoneal Carcinosis |
Recruiting |
NCT02493972
|
|
|
24 |
Primary Fascial Closure With Laparoscopic Ventral Hernia Repair: A Randomized Controlled Trial |
Active, not recruiting |
NCT02363790
|
|
|
25 |
Impact of the Systematic Closure of the Epigastric Trocar on Postoperative Incisional Hernia After Sleeve Gastrectomy Rate of First Intention. Monocentric Study, Before / After Prospective. |
Not yet recruiting |
NCT02973009
|
|
|
26 |
Sutureless vs Sutured Gastroschisis Closure |
Terminated |
NCT01094587
|
|
|
27 |
Randomized Clinical Trial of Early Delivery in Fetal Gastroschisis vs. Routine Care |
Terminated |
NCT01884324
|
|
|
28 |
Bedside Silo Versus Operative Closure for Gastroschisis |
Terminated |
NCT00404690
|
|
|
29 |
Prevention of Parenteral Nutrition-Associated Cholestasis With Cyclic Parenteral Nutrition in Infants |
Terminated |
NCT01062815
|
|
|
Cochrane evidence based reviews: gastroschisis
|